Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 5/20 | 0.48 |
| ▸ | MERTK | Q12866 | 3/20 | 0.48 |
| ▸ | TYRO3 | Q06418 | 15/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27315205 | 0.81 | NTRK1 (0.54) | AXLMERTKTYRO3CSNK2A2CSNK2A1 | |
| SCHEMBL27315261 | 0.80 | RET (0.47) | AXLMERTKTYRO3CSNK2A2CSNK2A1 | |
| SCHEMBL27315239 | 0.79 | RET (0.51) | AXLMERTKTYRO3AURKAAURKB | |
| SCHEMBL27315234 | 0.79 | RET (0.56) | AXLMERTKTYRO3 | |
| SCHEMBL27315133 | 0.75 | ACVRL1 (0.45) | AXLMERTKTYRO3CSNK2A2CSNK2A1 | |
| SCHEMBL27315088 | 0.73 | CSNK2A2 (0.43) | CSNK2A2CSNK2A1 | |
| SCHEMBL29927002 | 0.70 | ACVRL1 (0.46) | AXLMERTKTYRO3 | |
| SCHEMBL19429601 | 0.68 | TYRO3 (0.87) | AXLMERTKTYRO3 | |
| SCHEMBL29927100 | 0.67 | ERBB2 (0.59) | — | |
| SCHEMBL19429691 | 0.67 | TYRO3 (0.88) | AXLMERTKTYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4611900-A1 | RET-LDD PROTEIN INHIBITORS | Bristol-Myers Squibb Company (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024097980-A1 | RET-LDD PROTEIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-05-10 | — | — | WO | disclosed |